98%
921
2 minutes
20
Follicle-stimulating hormone (FSH) is central to reproduction in mammals. It acts through a G-protein-coupled receptor on the surface of target cells to stimulate testicular and ovarian functions. We present here the 2.9-A-resolution structure of a partially deglycosylated complex of human FSH bound to the extracellular hormone-binding domain of its receptor (FSHR(HB)). The hormone is bound in a hand-clasp fashion to an elongated, curved receptor. The buried interface of the complex is large (2,600 A2) and has a high charge density. Our analysis suggests that all glycoprotein hormones bind to their receptors in this mode and that binding specificity is mediated by key interaction sites involving both the common alpha- and hormone-specific beta-subunits. On binding, FSH undergoes a concerted conformational change that affects protruding loops implicated in receptor activation. The FSH-FSHR(HB) complexes form dimers in the crystal and at high concentrations in solution. Such dimers may participate in transmembrane signal transduction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514322 | PMC |
http://dx.doi.org/10.1038/nature03206 | DOI Listing |
Front Vet Sci
August 2025
Department of Biochemistry, Faculty of Biomedical Sciences, Kampala International University Western Campus, Bushenyi, Uganda.
Background: Male infertility is a global health issue, with pharmaceutical agents such as cimetidine contributing significantly to gonadotoxicity through antiandrogenic and oxidative mechanisms. The search for natural protective agents has highlighted var. (collard greens) for its antioxidant and endocrine-modulating properties.
View Article and Find Full Text PDFAnn Afr Med
September 2025
Department of Pathology, Dr. Lal Path Labs, New Delhi, India.
Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks.
View Article and Find Full Text PDFFront Pediatr
August 2025
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Background: Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.
Methods: This was a hospital data-based retrospective study.
Front Pharmacol
August 2025
The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
In recent years, the potential application of Hook f. (TWHF) in the treatment of rheumatoid arthritis (RA) has garnered increasing attention in both academic research and clinical practice. However, the effective use of is limited in clinical practice by its severe toxic side effects.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Gynecology/Obstetrics Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Introduction: Several studies indicate that a specific genotype profile could influence ovarian sensitivity to exogenous gonadotropin. However, most of the previous studies were observational and retrospective and thereby more prone to bias. The aim of this study was to evaluate the impact of gonadotropin single nucleotide polymorphisms (SNPs) on the outcomes of fertilization (IVF) in infertile patients undergoing their first ovarian stimulation (OS) cycle.
View Article and Find Full Text PDF